Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Study reveals why survival for blood cancer patients still varies between regions within Europe

Study reveals why survival for blood cancer patients still varies between regions within Europe

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Study shows promising results for new treatment approach in follicular lymphoma

Study shows promising results for new treatment approach in follicular lymphoma

Scientists show promising results for new treatment approach in follicular lymphoma

Scientists show promising results for new treatment approach in follicular lymphoma

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Combination therapy safe and active in follicular lymphoma

Combination therapy safe and active in follicular lymphoma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

FDA approves ibrutinib for treatment of mantle cell lymphoma

FDA approves ibrutinib for treatment of mantle cell lymphoma

FDA approves NDA filing for ibrutinib inhibitor in two B-cell malignancies

FDA approves NDA filing for ibrutinib inhibitor in two B-cell malignancies

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients